A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma.

@article{Ross2006ARM,
  title={A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma.},
  author={H. Ross and L. Hart and P. M. Swanson and M. Rarick and R. Figlin and A. D. Jacobs and D. McCune and A. Rosenberg and A. Baron and L. Grove and M. Thorn and D. Miller and J. Drachman and C. Rudin},
  journal={Lung cancer},
  year={2006},
  volume={54 1},
  pages={
          69-77
        }
}
  • H. Ross, L. Hart, +11 authors C. Rudin
  • Published 2006
  • Medicine
  • Lung cancer
  • PURPOSE Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC). Targeted therapies may improve chemotherapy effectiveness without worsening toxicity. SGN-15 is an antibody-drug conjugate (ADC), consisting of a chimeric murine monoclonal antibody recognizing the Lewis Y (Le(y)) antigen, conjugated to doxorubicin. Le(y) is an attractive target since it is expressed by most NSCLC. SGN-15 was… CONTINUE READING
    30 Citations
    Will targeted therapy hold its promise? An evidence-based review
    • 47
    Targeting Lewis Y (Ley) in Small Cell Lung Cancer with a Humanized Monoclonal Antibody, hu3S193: A Pilot Trial Testing Two Dose Levels
    • L. Krug, D. Milton, +11 authors C. Divgi
    • Medicine
    • Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
    • 2007
    • 23
    Investigational Antibody–Drug Conjugates for Treatment of B‐lineage Malignancies
    • 16
    Doxorubicin conjugates for selective delivery to tumors.
    • 14
    A Population-Based Clinical Trial of Irinotecan and Carboplatin
    • PDF

    References

    SHOWING 1-10 OF 20 REFERENCES
    Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors.
    • 139
    Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.
    • N. Hanna, F. Shepherd, +17 authors P. Bunn
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2004
    • 2,247
    Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
    • 2,042
    Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504.
    • 344
    Erlotinib in previously treated non-small-cell lung cancer.
    • 3,704
    • PDF
    Enhanced antitumor activity of paclitaxel in combination with the anticarcinoma immunoconjugate BR96-doxorubicin.
    • 39
    • PDF
    Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
    • 4,420
    • PDF